Study: Experimental Alzheimer’s drug slows decline

Published: May. 3, 2023 at 9:28 AM CDT
Email This Link
Share on Pinterest
Share on LinkedIn

(CNN) - Drugmaker Eli Lilly says it has made a major breakthrough in treatment for Alzheimer’s disease and is planning to submit its drug for the Food and Drug Administration’s approval next month.

In a clinical trial, the company’s medicine Donanemab found progression of the disease slowed by 35% over the course of 18 months.

The drug is an antibody that is injected into the blood.

It travels to the brain and finds and binds plaques linked to Alzheimer’s.

The body’s own immune system then clears away the plaque.

According to Eli Lilly, about half of the patients achieved plaque clearance after one year and 72% achieved it in 18 months.

Eli Lilly did report some side effects, and three people died during the trial.